Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.

Autor: Baetz T; a Department of Oncology, Cancer Centre of Southeastern Ontario , Queen's University , Kingston , ON , Canada., Chen BE; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Couban S; c Queen Elizabeth II Heath Sciences Centre , Halifax , NS , Canada., Tom Kouroukis C; d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada., Buckstein R; e Department of Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre , University of Toronto , Toronto , ON , Canada., Kuruvilla J; f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada., Howson-Jan K; g London Health Sciences Centre , London , ON , Canada., Szwajcer D; h Department of Medicine , University of Manitoba , Winnipeg , MB , Canada., Federico M; i Cattedra Di Oncologia Medica , Università Di Modena E Reggio Emilia , Modena , Italy., Meyer RM; d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada., Djurfeldt MS; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Hay AE; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Shepherd L; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Crump M; f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2017 Jan; Vol. 58 (1), pp. 64-69. Date of Electronic Publication: 2016 Jun 07.
DOI: 10.1080/10428194.2016.1187274
Abstrakt: The impact of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant (ASCT) was evaluated in a retrospective subgroup analysis of NCIC CTG LY.12. Among 414 patients who relapsed following R-CHOP, 96 received salvage chemotherapy alone [R - cohort]; and 318 received rituximab with chemotherapy [R + cohort] following a protocol amendment. The R-cohort had a higher proportion of patients with PS ≥2 and relapse <1 year after R-CHOP. The response rate (45.6% vs. 25.0%, p = 0.0003), CR/CRu (15.7% vs. 4.2%, p = 0.003) and transplantation rate (51.9% vs. 31.3%, p = 0.0004) was higher in the R + cohort. Event-free (27% vs. 22%, p = 0.0954) and overall survival at four years (43% vs. 31%; p = 0.045) were greater in the R + cohort when the patients with best response SD/PD to R-CHOP were excluded. Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje